Physician profile
Latrice M Roberts
NPI 1245626910
$5,848.78
in general payments reported to CMS, 2019-2025
45 companies · $1,168 in 2025
The $1,168 reported for 2025 was more than what 92% of Geriatric Medicine (Family Medicine) providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $233 · 2020: $706 · 2021: $1,007 · 2022: $1,010 · 2023: $841 · 2024: $883 · 2025: $1,168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,893.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,892.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,167.76 | 2019-2025 | Repatha, Otezla, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $467.50 | 2020-2025 | Relistor |
| Pfizer INC. | $345.99 | 2019-2024 | |
| Abbvie INC. | $340.63 | 2021-2025 | |
| Glaxosmithkline, LLC. | $316.72 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $307.85 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Otsuka America Pharmaceutical, INC. | $243.96 | 2023-2025 | Rexulti, Nuedexta |
| Novo Nordisk INC | $206.42 | 2019-2024 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $201.13 | 2021-2025 | Verquvo, Belsomra, Steglatro |
| Astellas Pharma US INC | $166.07 | 2023-2025 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $158.05 | 2020-2025 | Invega Sustenna |
| Vanda Pharmaceuticals INC. | $157.31 | 2024-2025 | Fanapt |
| Bayer Healthcare Pharmaceuticals INC. | $156.45 | 2022-2025 | |
| Axsome Therapeutics, INC. | $141.61 | 2023-2025 | Auvelity, Sunosi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.10 | 2019-2023 | Jardiance |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Latrice Roberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.